The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Sponsor content
99 result(s) found, displaying 1 to 10
-
Jan-2025Prescription medicine evaluationActive ingredient: Seladelpar lysine dihydrate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HEPCLUDEX bulevirtide (as acetate) 2 mg powder for injection vial.
-
Cancellation by sponsorRequested by Gilead Sciences Pty Ltd
-
Cancellation by sponsorRequested by Gilead Sciences Pty Ltd
-
Cancellation by sponsorRequested by Gilead Sciences Pty Ltd
-
Cancellation by sponsorRequested by Gilead Sciences Pty Ltd
-
Sep-2024Prescription medicine evaluationActive ingredient: bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate.
-
Prescription medicine decision summaryHepcludex (bulevirtide acetate) was approved to treat chronic hepatitis delta virus infection in adults with compensated liver disease.
-
Prescription medicine registrationActive ingredients: bulevirtide acetate.
-
Cancellation by sponsorRequested by Gilead Sciences Pty Ltd
Pages
- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »